Search / Trial NCT06234150

Aerobic Dance During Chemotherapy in Breast Cancer Patients With Cognitive Impairment

Launched by THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY · Jan 23, 2024

Trial Information

Current as of October 09, 2024

Not yet recruiting

Keywords

Description

BACKGROUND: Cancer-related cognitive impairment (CRCI) is often reported in breast cancer patients and is characterized by a decline in cognitive functions including memory, processing speed, attention, and executive function. Despite the fact that chemotherapy is a significant cause of CRCI, recent studies have shown that 20-30% of patients may already have cognitive decline prior to chemotherapy and that chemotherapy may exacerbate cognitive impairment in these patients. These findings highlight the importance of providing these patients with appropriate interventions while undergoing che...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • * 18-65 years old
  • * Newly diagnosed, histologically confirmed, resected stage I-IIIa BC
  • * Scheduled for chemotherapy with Epirubicin+ Cyclophosphamide (EC) regimen
  • * Presence of objective cognitive decline
  • Exclusion Criteria:
  • * Regular exercise habits (exercise at moderate intensity for 30 minutes a day, 3 days a week, for at least 3 months.),
  • * Motor dysfunction
  • * Alzheimer's disease
  • * Vascular dementia

About The First Affiliated Hospital With Nanjing Medical University

The First Affiliated Hospital of Nanjing Medical University is a leading medical institution dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital is committed to implementing rigorous scientific methodologies to evaluate new therapies and treatment approaches. With a multidisciplinary team of experienced healthcare professionals and researchers, the hospital fosters a collaborative environment aimed at enhancing patient outcomes and contributing to the global medical community. Its strategic focus on translational medicine ensures that groundbreaking discoveries are efficiently translated into practical applications for patient care.

Locations

Nanjing, Jiangsu, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0